Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rectal dose constraints for salvage iodine-125 prostate brachytherapy.
Peters M, Hoekstra CJ, van der Voort van Zyp JR, Westendorp H, van de Pol SM, Moerland MA, Maenhout M, Kattevilder R, van Vulpen M. Peters M, et al. Among authors: maenhout m. Brachytherapy. 2016 Jan-Feb;15(1):85-93. doi: 10.1016/j.brachy.2015.10.004. Epub 2015 Nov 21. Brachytherapy. 2016. PMID: 26614233
Development and internal validation of a multivariable prediction model for biochemical failure after whole-gland salvage iodine-125 prostate brachytherapy for recurrent prostate cancer.
Peters M, van der Voort van Zyp JRN, Moerland MA, Hoekstra CJ, van de Pol S, Westendorp H, Maenhout M, Kattevilder R, Verkooijen HM, van Rossum PSN, Ahmed HU, Shah TT, Emberton M, van Vulpen M. Peters M, et al. Among authors: maenhout m. Brachytherapy. 2016 May-Jun;15(3):296-305. doi: 10.1016/j.brachy.2016.01.004. Epub 2016 Mar 2. Brachytherapy. 2016. PMID: 26948662
Focal salvage iodine-125 brachytherapy for prostate cancer recurrences after primary radiotherapy: a retrospective study regarding toxicity, biochemical outcome and quality of life.
Peters M, Maenhout M, van der Voort van Zyp JR, Moerland MA, Moman MR, Steuten LM, van Deursen MJ, van Vulpen M. Peters M, et al. Among authors: maenhout m. Radiother Oncol. 2014 Jul;112(1):77-82. doi: 10.1016/j.radonc.2014.06.013. Epub 2014 Jul 3. Radiother Oncol. 2014. PMID: 24998704
Multivariable model development and internal validation for prostate cancer specific survival and overall survival after whole-gland salvage Iodine-125 prostate brachytherapy.
Peters M, van der Voort van Zyp JR, Moerland MA, Hoekstra CJ, van de Pol S, Westendorp H, Maenhout M, Kattevilder R, Verkooijen HM, van Rossum PS, Ahmed HU, Shah TT, Emberton M, van Vulpen M. Peters M, et al. Among authors: maenhout m. Radiother Oncol. 2016 Apr;119(1):104-10. doi: 10.1016/j.radonc.2016.02.002. Epub 2016 Feb 17. Radiother Oncol. 2016. PMID: 26897512 Free article.
Second salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer.
Maenhout M, van Vulpen M, Moerland M, Peters M, Meijer R, van den Bosch M, Nguyen P, Frank S, van der Voort van Zyp J. Maenhout M, et al. J Contemp Brachytherapy. 2017 Apr;9(2):161-166. doi: 10.5114/jcb.2017.67015. Epub 2017 Apr 3. J Contemp Brachytherapy. 2017. PMID: 28533806 Free PMC article.
18 results